Benefiber ‘Helps Maintain Regularity’ Claim Fails NAD Review; Decision Appealed
This article was originally published in The Tan Sheet
Executive Summary
Novartis Health disagrees with the National Advertising Division decision that the Benefiber express claim “helps maintain regulatory” is not supported by research and will appeal the decision. NAD reviewed the claim made in a challenge by Metamucil fiber supplement marketer P&G.
You may also be interested in...
GSK's Benefiber Constipation-Relief Claim Supported In Review Following P&G Challenge
GSK supported claim Benefiber Healthy Balance supplement "helps relieve occasional constipation and abdominal discomfort without causing diarrhea" in challenge by Metamucil marketer P&G. Dispute decided in industry self-regulation form focused on PHGG's mechanism of action in reliving constipation.
Neurocet Cliff's Notes Fail NAD Test For 'Stronger Than Morphine' Claim
NAD says direct advertising claims for the Neurocet supplement rely on insufficient or ill-fitted research – including summaries – and marketer National Media Group should discontinue numerous statements challenged by the Council for Responsible Nutrition.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.